A new study published in the Journal of American Medical Association showed that nirsevimab offers protection against a ...

Nirsevimab-resistant respiratory syncytial virus variants remain rare, but continued molecular surveillance is crucial. Read ...

Immunisation with nirsevimab reduced bronchiolitis-related hospitalisations among infants younger than 3 months who visited the emergency department (ED), according to a new study. Nirsevimab also ...

Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV) season received protection with either nirsevimab or exposure to maternal RSVpreF, with maternal RSVpreF ...

A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

The incident occurred months after health authorities discovered the GP’s clinic had incorrectly stored vaccines, potentially ...

Nirsevimab is a long-acting monoclonal antibody designed to provide passive immunity against RSV in infants and young children. The Advisory Committee on Immunization Practices (ACIP) recommends ...

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

Getting vaccinated during pregnancy protects your newborn from severe infection during the first critical months of life.

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.

In the new study, 64% of pregnant people were vaccinated before giving birth, and 70% of newly born eligible babies got a monoclonal antibody treatment called nirsevimab. Combined, 80% of babies ...

Vermont has the second lowest state fatality rate in the US (146.3 per 100K; Hawaii 112.7/100K). Mississippi (462.8/100K) and ...